Literature DB >> 23666762

Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.

Gucci Jijuan Gu1, Harald Lund, Di Wu, Andries Blokzijl, Christina Classon, Gabriel von Euler, Ulf Landegren, Dan Sunnemark, Masood Kamali-Moghaddam.   

Abstract

The microtubule-affinity regulating kinase (MARK) family consists of four highly conserved members that have been implicated in phosphorylation of tau protein, causing formation of neurofibrillary tangles in Alzheimer's disease (AD). Understanding of roles by individual MARK isoform in phosphorylating tau has been limited due to lack of antibodies selective for each MARK isoform. In this study, we first applied the proximity ligation assay on cells to select antibodies specific for each MARK isoform. In cells, a CagA peptide specifically and significantly inhibited tau phosphorylation at Ser²⁶² mediated by MARK4 but not other MARK isoforms. We then used these antibodies to study expression levels of MARK isoforms and interactions between tau and individual MARK isoforms in postmortem human brains. We found a strong and significant elevation of MARK4 expression and MARK4-tau interactions in AD brains, correlating with the Braak stages of the disease. These results suggest the MARK4-tau interactions are of functional importance in the progression of AD and the results also identify MARK4 as a promising target for AD therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666762     DOI: 10.1007/s12017-013-8232-3

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  21 in total

1.  Intercellular variation in signaling through the TGF-β pathway and its relation to cell density and cell cycle phase.

Authors:  Agata Zieba; Katerina Pardali; Ola Söderberg; Lena Lindbom; Erik Nyström; Aristidis Moustakas; Carl-Henrik Heldin; Ulf Landegren
Journal:  Mol Cell Proteomics       Date:  2012-03-22       Impact factor: 5.911

2.  Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons.

Authors:  R F Moroni; S De Biasi; P Colapietro; L Larizza; A Beghini
Journal:  Neuroscience       Date:  2006-09-14       Impact factor: 3.590

3.  Western blotting via proximity ligation for high performance protein analysis.

Authors:  Yanling Liu; Jijuan Gu; Åsa Hagner-McWhirter; Poojahrau Sathiyanarayanan; Mats Gullberg; Ola Söderberg; Johan Johansson; Maria Hammond; Daniel Ivansson; Ulf Landegren
Journal:  Mol Cell Proteomics       Date:  2011-08-02       Impact factor: 5.911

4.  A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.

Authors:  Wendou Yu; Jai Polepalli; Dhananjay Wagh; Jayakumar Rajadas; Robert Malenka; Bingwei Lu
Journal:  Hum Mol Genet       Date:  2011-12-08       Impact factor: 6.150

5.  Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study.

Authors:  J Y Chin; R B Knowles; A Schneider; G Drewes; E M Mandelkow; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2000-11       Impact factor: 3.685

6.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

7.  Direct observation of individual endogenous protein complexes in situ by proximity ligation.

Authors:  Ola Söderberg; Mats Gullberg; Malin Jarvius; Karin Ridderstråle; Karl-Johan Leuchowius; Jonas Jarvius; Kenneth Wester; Per Hydbring; Fuad Bahram; Lars-Gunnar Larsson; Ulf Landegren
Journal:  Nat Methods       Date:  2006-10-29       Impact factor: 28.547

8.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.

Authors:  Jose M Lizcano; Olga Göransson; Rachel Toth; Maria Deak; Nick A Morrice; Jérôme Boudeau; Simon A Hawley; Lina Udd; Tomi P Mäkelä; D Grahame Hardie; Dario R Alessi
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

9.  The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.

Authors:  Maria-Magdalena Mocanu; Astrid Nissen; Katrin Eckermann; Inna Khlistunova; Jacek Biernat; Dagmar Drexler; Olga Petrova; Kai Schönig; Hermann Bujard; Eckhard Mandelkow; Lepu Zhou; Gabriele Rune; Eva-Maria Mandelkow
Journal:  J Neurosci       Date:  2008-01-16       Impact factor: 6.167

10.  Helicobacter pylori CagA inhibits PAR1-MARK family kinases by mimicking host substrates.

Authors:  Dragana Nesić; Marshall C Miller; Zachary T Quinkert; Markus Stein; Brian T Chait; C Erec Stebbins
Journal:  Nat Struct Mol Biol       Date:  2009-12-06       Impact factor: 15.369

View more
  22 in total

Review 1.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

2.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

3.  Proteomic Investigation of Murine Neuronal α7-Nicotinic Acetylcholine Receptor Interacting Proteins.

Authors:  Matthew J Mulcahy; Joao A Paulo; Edward Hawrot
Journal:  J Proteome Res       Date:  2018-10-04       Impact factor: 4.466

4.  De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease.

Authors:  A Rovelet-Lecrux; C Charbonnier; D Wallon; G Nicolas; M N J Seaman; C Pottier; S Y Breusegem; P P Mathur; P Jenardhanan; K Le Guennec; A S Mukadam; O Quenez; S Coutant; S Rousseau; A-C Richard; A Boland; J-F Deleuze; T Frebourg; D Hannequin; D Campion
Journal:  Mol Psychiatry       Date:  2015-07-21       Impact factor: 15.992

Review 5.  Protein phosphorylation in neurodegeneration: friend or foe?

Authors:  Sandra Tenreiro; Katrin Eckermann; Tiago F Outeiro
Journal:  Front Mol Neurosci       Date:  2014-05-13       Impact factor: 5.639

6.  Tyrosine phosphorylation profiling via in situ proximity ligation assay.

Authors:  Lioudmila Elfineh; Christina Classon; Anna Asplund; Ulf Pettersson; Masood Kamali-Moghaddam; Sara Bergström Lind
Journal:  BMC Cancer       Date:  2014-06-13       Impact factor: 4.430

Review 7.  Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases.

Authors:  Baohua Liu; Jing Ruan; Meng Chen; Zhongding Li; Gloria Manjengwa; Dirk Schlüter; Weihong Song; Xu Wang
Journal:  Mol Psychiatry       Date:  2021-07-20       Impact factor: 15.992

8.  Oral (-)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3β.

Authors:  Katriona L Hole; Lydia E Staniaszek; Gayathri Menon Balan; Jody M Mason; Jon T Brown; Robert J Williams
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 9.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

10.  MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

Authors:  Harald Lund; Elin Gustafsson; Anne Svensson; Maria Nilsson; Margareta Berg; Dan Sunnemark; Gabriel von Euler
Journal:  Acta Neuropathol Commun       Date:  2014-02-17       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.